THE CARDIOSPLENIC AXIS IS ESSENTIAL FOR THE PATHOGENESIS OF ISCHEMIC HEART FAILURE

Sumanth D Prabhu1

  • 1BIRMINGHAM, ALABAMA.

Insights

Heart failure involves immune cells like T cells and macrophages. The spleen plays a key role in this immune response, driving inflammation and cardiac remodeling in ischemic cardiomyopathy.

Area of Science:

  • Immunology
  • Cardiology
  • Pathology

Background:

  • The role of the immune system in heart failure (HF) pathogenesis remains unclear.
  • Innate and adaptive immune responses are critical in many diseases, but their specific involvement in HF is not well-defined.

Purpose of the Study:

  • To investigate the involvement of innate and adaptive immunity in the development of ischemic heart failure (HF).
  • To elucidate the role of the spleen and splenic immune cells in HF progression and cardiac remodeling.

Main Methods:

  • Analysis of immune cell populations (monocytes, macrophages, dendritic cells, T cells) in mice with ischemic HF.
  • Assessment of splenic remodeling and antigen processing.
  • Experimental manipulations including splenectomy, adoptive transfer of splenocytes and T cells, and T cell depletion.

Main Results:

  • Ischemic HF mice showed significant expansion of proinflammatory monocytes/macrophages, dendritic cells, and CD4+/CD8+ T cells.
  • The spleen exhibited remodeling with heightened antigen processing and expanded antigen-experienced effector/memory CD4+ T cells.
  • Activated splenic immune cells were found to drive chronic inflammation, traffic to the heart, and promote pathological cardiac remodeling.

Conclusions:

  • The spleen is central to the immune response in HF, with activated splenic immune cells contributing to chronic inflammation and cardiac remodeling.
  • Ischemic cardiomyopathy may be an immune-mediated disease targeting cardiac antigens, with the spleen playing a critical role.
  • Immune memory within splenic cells contributes to tissue injury and pathological cardiac remodeling in HF.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
952
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
983
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330